Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.55 |
| ▸ | ENPEP | Q07075 | 11/20 | 0.37 |
| ▸ | ANPEP | P15144 | 5/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28547750 | 1.00 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| SCHEMBL29969213 | 0.87 | PTGS1 (0.54) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| SCHEMBL2941633 | 0.83 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| SCHEMBL2941639 | 0.83 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| SCHEMBL31130601 | 0.81 | — | — | |
| SCHEMBL359013 | 0.81 | — | — | |
| SCHEMBL28440494 | 0.81 | — | — | |
| SCHEMBL2941641 | 0.81 | — | — | |
| SCHEMBL8289201 | 0.80 | — | — | |
| SCHEMBL29581937 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0739208-A1 | FLAVIN DERIVATIVES AS ANTI-VIRAL AGENTS | RADOPATH LIMITED (GB) | 1996-10-30 | — | — | EP | claimed |
| WO-1995011028-A1 | FLAVIN DERIVATIVES AS ANTI-VIRAL AGENTS | RADOPATH LIMITED (GB) | 1995-04-27 | — | — | WO | claimed |
| CN-118201957-A | FC binding polypeptides | 思拓凡生物工艺研发有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118105461-A | Treatment of abdominal pain associated with diarrhea predominant irritable bowel syndrome | 硬木药品公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117530912-A | Stable solid formulations of guanylate cyclase-C receptor agonist polypeptides suitable for oral administration | 硬木药品公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-4281775-A1 | SYSTEMS AND METHODS FOR BIOMOLECULE PREPARATION | Nautilus Subsidiary, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3191581-B9 | TARGETED MUTAGENESIS IN SPIRULINA | LUMEN BIOSCIENCE INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230212322-A1 | SYSTEMS AND METHODS FOR BIOMOLECULE PREPARATION | NAUTILUS SUBSIDIARY, INC. | 2023-07-06 | — | — | US | disclosed |
| EP-3191581-B1 | TARGETED MUTAGENESIS IN SPIRULINA | LUMEN BIOSCIENCE INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-115089556-A | Delayed release compositions of linaclotide | 硬木药品公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220227890-A1 | SYSTEMS AND METHODS FOR BIOMOLECULE PREPARATION | NAUTILUS SUBSIDIARY, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20040009559-A1 | Multifunctional recombinant phycobiliprotein-based fluorescent constructs and phycobilisome display | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-01-15 | — | — | US | disclosed |
| US-6649376-B1 | Fusion protein incorporated into macromolecular structure; do not form inclusion bodies; assists folding process; use in labeling | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-11-18 | — | — | US | disclosed |
| EP-1240314-A4 | MULTIFUNCTIONAL RECOMBINANT PHYCOBILIPROTEIN-BASED FLUORESCENT CONSTRUCTS AND PHYCOBILISOME DISPLAY | UNIV CALIFORNIA (US) | 2003-02-26 | — | — | EP | disclosed |
| WO-2003012448-A1 | ENGINEERING OF LIVING CELLS FOR THE EXPRESSION OF HOLO-PHYCOBILIPROTEIN-BASED CONSTRUCTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20030027285-A1 | Engineering of living cells for the expression of holo-phycobiliprotein-based constructs | ENERGY, U.S. DEPARTMENT OF | 2003-02-06 | — | — | US | disclosed |
| EP-1240314-A1 | MULTIFUNCTIONAL RECOMBINANT PHYCOBILIPROTEIN-BASED FLUORESCENT CONSTRUCTS AND PHYCOBILISOME DISPLAY | The Regents of the University of California (US) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046395-A1 | MULTIFUNCTIONAL RECOMBINANT PHYCOBILIPROTEIN-BASED FLUORESCENT CONSTRUCTS AND PHYCOBILISOME DISPLAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-06-28 | — | — | WO | disclosed |
| US-6051549-A | POLYPEPTIDE; ANTITUMOR, ANTICANCER AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-04-18 | — | — | US | disclosed |
| US-5770563-A | ANTIPROLIFERATIVE AGENTS, ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227890-A1 | SYSTEMS AND METHODS FOR BIOMOLECULE PREPARATION | PSAP, NPEPPS, VIP | PTGS1 3090/4885SLC7A11 4451/4885ENPEP 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.